Topotecane [Inn-French] en es it fr

Topotecane [Inn-French] Brand names, Topotecane [Inn-French] Analogs

Topotecane [Inn-French] Brand Names Mixture

  • No information avaliable

Topotecane [Inn-French] Chemical_Formula


Topotecane [Inn-French] RX_link

Topotecane [Inn-French] fda sheet

Topotecane_[Inn-French] FDA

Topotecane [Inn-French] msds (material safety sheet)

Topotecane_[Inn-French] MSDS

Topotecane [Inn-French] Synthesis Reference

No information avaliable

Topotecane [Inn-French] Molecular Weight

421.446 g/mol

Topotecane [Inn-French] Melting Point

213-218 oC

Topotecane [Inn-French] H2O Solubility

1 mg/ml

Topotecane [Inn-French] State


Topotecane [Inn-French] LogP


Topotecane [Inn-French] Dosage Forms

Powder for solution

Topotecane [Inn-French] Indication

For the treatment of metastatic carcinoma of the ovary and small cell lung cancer following the failure of first-line chemotherapy.

Topotecane [Inn-French] Pharmacology

Topotecan, a semi-synthetic derivative of camptothecin (a plant alkaloid obtained from the Camptotheca acuminata tree), is an anti-tumor drug with topoisomerase I-inhibitory activity similar to irinotecan. Topotecan interferes with the growth of cancer cells, which are eventually destroyed. Since the growth of normal cells may also be affected by the medicine, other effects may also occur. Unlike irinotecan, topotecan is found predominantly in the inactive carboxylate form at neutral pH and it is not a prodrug.

Topotecane [Inn-French] Absorption

No information avaliable

Topotecane [Inn-French] side effects and Toxicity

The primary anticipated complication of overdosage would consist of bone marrow suppression.

Topotecane [Inn-French] Patient Information

No information avaliable

Topotecane [Inn-French] Organisms Affected

Humans and other mammals